Progestins increase endogenous opioid peptide activity in postmenopausal women

J Clin Endocrinol Metab. 1985 Jan;60(1):34-6. doi: 10.1210/jcem-60-1-34.

Abstract

To determine the effect of administration of a progestin alone on endogenous opioid peptide activity, we infused naloxone (2 mg/h for 4 h) into seven estrogen-deficient postmenopausal women before and after oral medroxyprogesterone acetate (Provera; 20 mg) daily for 30 days. Baseline serum LH levels were significantly decreased by the Provera therapy [70.3 +/- 6.6 (+/- SE) vs. 27.5 +/- 1.7 mIU/ml; P less than 0.001]. Naloxone infusion before Provera treatment had no effect on serum LH levels. In contrast, after Provera therapy, a significant (P less than 0.001) increase in LH levels toward the pre-Provera baseline occurred with naloxone infusion. These findings suggest that progestins exert their negative feedback effects on LH at least in part through an opioid peptide-mediated mechanism and that progestin treatment alone can reestablish opiatergic control of LH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Endorphins / physiology*
  • Estradiol / blood
  • Estradiol / deficiency
  • Estrone / blood
  • Estrone / deficiency
  • Female
  • Humans
  • Luteinizing Hormone / blood
  • Medroxyprogesterone / analogs & derivatives
  • Medroxyprogesterone / pharmacology
  • Medroxyprogesterone Acetate
  • Menopause*
  • Middle Aged
  • Naloxone / pharmacology
  • Progestins / pharmacology*
  • Prolactin / blood

Substances

  • Endorphins
  • Progestins
  • Estrone
  • Naloxone
  • Estradiol
  • Prolactin
  • Luteinizing Hormone
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone